---
title: "Vita Life Sciences to Cancel 658,502 Employee Incentive Shares in Targeted Buy-Back"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284312178.md"
description: "Vita Life Sciences Limited (AU:VLS) announced a buy-back of 658,502 unquoted shares from its employee Long Term Incentive Plan, following performance hurdles met by key executives. The buy-back price is $2.5323 per share, based on a 10-day average. This action aims to refine the company's capital structure and align executive interests with shareholders, with minimal impact on share capital and liquidity. Remaining shares will convert to ordinary shares, enhancing the company's market presence in the healthcare sector."
datetime: "2026-04-28T04:48:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284312178.md)
  - [en](https://longbridge.com/en/news/284312178.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284312178.md)
generator: "portal-rs"
---

# Vita Life Sciences to Cancel 658,502 Employee Incentive Shares in Targeted Buy-Back

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Vita Life Sciences Limited ( (AU:VLS) ) just unveiled an update.

Vita Life Sciences will buy back 658,502 unquoted shares issued under its employee Long Term Incentive Plan, following the satisfaction of performance hurdles attached to 875,000 plan shares granted in 2024 to six key executives, including Managing Director Mr. O’Keefe. The buy-back price is set at $2.5323 per share, based on the 10-day volume-weighted average on the ASX, and the repurchased shares will be cancelled with minimal impact on share capital and no effect on cash reserves.

Of the remaining 216,498 plan shares, 66,498 will convert to ordinary shares and be quoted on the ASX for five executives, while an executive holding 150,000 plan shares intends to repay the associated loan by 30 June 2026 so those shares can also become quoted ordinary shares. The move fine-tunes the company’s capital structure while fulfilling obligations under its incentive scheme, aligning executive interests with shareholders without straining liquidity. 

**More about Vita Life Sciences Limited**

Vita Life Sciences Limited operates in the healthcare and life sciences sector, focusing on nutraceuticals and health products distributed primarily through retail and pharmacy channels in Australia and selected Asian markets. The company targets consumers seeking preventive health solutions and leverages long-term incentive plans to retain and reward key executives.

**Average Trading Volume:** 19,565

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** A$140.3M

Learn more about VLS stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [VLS.AU](https://longbridge.com/en/quote/VLS.AU.md)

## Related News & Research

- [Mercialys: Declaration of Transactions in Own Shares From September 2, 2026 to September 4, 2026 Inclusive](https://longbridge.com/en/news/298229687.md)
- [Iguatemi board member cuts IGTI11 units stake by R$ 1.3 million in August sales](https://longbridge.com/en/news/298662019.md)
- [Orizon controller stake slips by R$ 62,693 on August spot share sales](https://longbridge.com/en/news/298657288.md)
- [ProVen VCT allots 1,148,536 shares at average price 61.41p in subscription offer](https://longbridge.com/en/news/298734409.md)
- [Citi Keeps Their Hold Rating on Cochlear  (CHEOF)](https://longbridge.com/en/news/298516761.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**